<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>30</volume><submitter>Bastone AL</submitter><funding>Deutsche Forschungsgemeinschaft</funding><funding>Lower Saxony State Ministry of Science and Culture</funding><funding>Horizon 2020</funding><pubmed_abstract>Safety assessment in retroviral vector-mediated gene therapy remains challenging. In clinical trials for different blood and immune disorders, insertional mutagenesis led to myeloid and lymphoid leukemia. We previously developed the &lt;i>In Vitro&lt;/i> Immortalization Assay (IVIM) and Surrogate Assay for Genotoxicity Assessment (SAGA) for pre-clinical genotoxicity prediction of integrating vectors. Murine hematopoietic stem and progenitor cells (mHSPCs) transduced with mutagenic vectors acquire a proliferation advantage under limiting dilution (IVIM) and activate stem cell- and cancer-related transcriptional programs (SAGA). However, both assays present an intrinsic myeloid bias due to culture conditions. To detect lymphoid mutants, we differentiated mHSPCs to mature T cells and analyzed their</pubmed_abstract><journal>Molecular therapy. Methods &amp; clinical development</journal><pagination>515-533</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10491817</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development of an &lt;i>in vitro&lt;/i> genotoxicity assay to detect retroviral vector-induced lymphoid insertional mutants.</pubmed_title><pmcid>PMC10491817</pmcid><pubmed_authors>Dittrich-Breiholz O</pubmed_authors><pubmed_authors>Dziadek V</pubmed_authors><pubmed_authors>Mansel F</pubmed_authors><pubmed_authors>Bastone AL</pubmed_authors><pubmed_authors>Fleischauer J</pubmed_authors><pubmed_authors>Schwarzer A</pubmed_authors><pubmed_authors>Schambach A</pubmed_authors><pubmed_authors>John-Neek P</pubmed_authors><pubmed_authors>Agyeman-Duah E</pubmed_authors><pubmed_authors>Rothe M</pubmed_authors><pubmed_authors>Schaudien D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of an &lt;i>in vitro&lt;/i> genotoxicity assay to detect retroviral vector-induced lymphoid insertional mutants.</name><description>Safety assessment in retroviral vector-mediated gene therapy remains challenging. In clinical trials for different blood and immune disorders, insertional mutagenesis led to myeloid and lymphoid leukemia. We previously developed the &lt;i>In Vitro&lt;/i> Immortalization Assay (IVIM) and Surrogate Assay for Genotoxicity Assessment (SAGA) for pre-clinical genotoxicity prediction of integrating vectors. Murine hematopoietic stem and progenitor cells (mHSPCs) transduced with mutagenic vectors acquire a proliferation advantage under limiting dilution (IVIM) and activate stem cell- and cancer-related transcriptional programs (SAGA). However, both assays present an intrinsic myeloid bias due to culture conditions. To detect lymphoid mutants, we differentiated mHSPCs to mature T cells and analyzed their</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Sep</publication><modification>2026-05-28T15:28:34.679Z</modification><creation>2025-04-07T03:29:14.911Z</creation></dates><accession>S-EPMC10491817</accession><cross_references><pubmed>37693949</pubmed><doi>10.1016/j.omtm.2023.08.017</doi></cross_references></HashMap>